Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9884253 | 0.91 | PIK3CD (0.81) | PIK3CDPIK3CGPIK3CAPIK3CBBTK | |
| SCHEMBL9884070 | 0.82 | PIK3CD (0.93) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9924626 | 0.82 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884102 | 0.82 | PIK3CG (0.85) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL30115074 | 0.82 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL958592 | 0.82 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL23287755 | 0.81 | PIK3CD (0.73) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL29479406 | 0.81 | PIK3CG (0.72) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL955596 | 0.81 | PIK3CG (0.72) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884149 | 0.81 | PIK3CD (0.86) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | PIK3CA, MCL1, PIK3CB | PIK3CD 4/4885PIK3CG 6/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.